Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

About FDA

FDA approves changes in the Avastin (beacizumab) package insert

Recent changes have been made to the Avastin Injection prescription information.  These changes include:

  • Warnings regarding the occurrence of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving Avastin
  • Recommendation for Avastindiscontinuation in patients who develop RPLS
  • Addition of Nasal Septum Perforation as a Serious Adverse Event in patients receiving Avastin

Full prescribing information, including the above changes, is available in Drugs@FDA 

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by phone at 1-800-FDA-1088, by facsimile 1-800-FDA-0178, by mail, or by using the Form 3500 


Page Last Updated: 12/29/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English